Anti-IL-6 Versus Anti-IL-6R Blocking Antibodies to Treat Acute Ebola Infection in BALB/c Mice: Potential Implications for Treating Cytokine Release Syndrome

Anti-IL-6 Versus Anti-IL-6R Blocking Antibodies to Treat Acute Ebola Infection in BALB/c Mice: Potential Implications for Treating Cytokine Release Syndrome

Cytokine release syndrome (CRS) is known to be a factor in morbidity and mortality associated with acute viral infections including those caused by filoviruses and coronaviruses. IL-6 has been implicated as a cytokine negatively associated with survival after filovirus and coronavirus infection. How...

Full description

Bibliographic Details
Main Authors: Reid Rubsamen, Scott Burkholz, Christopher Massey, Trevor Brasel, Tom Hodge, Lu Wang, Charles Herst, Richard Carback, Paul Harris
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-09-01
Series:Frontiers in Pharmacology
Subjects:
Ebola (EBOV)
COVID-19
SARS-CoV-2
Anti-IL-6
Anti-IL-6R
cytokine release syndrome
Online Access:https://www.frontiersin.org/article/10.3389/fphar.2020.574703/full

Internet

https://www.frontiersin.org/article/10.3389/fphar.2020.574703/full

Similar Items